I-Mab IMAB

NAS: IMAB | ISIN: US44975P1030 15:55

1,790 USD (-0,55%)

(-0,55%) 15:55

Grafiek I-Mab

Grafiek I-Mab

1 dag1d -0,55%
1 week1w -0,55%
1 maand1m -1,10%
3 maanden3m -2,18%
6 maanden6m 38,77%
1 jaar1j -43,17%
5 jaar5j -85,68%

I-Mab in het nieuws

Toon enkel gratis nieuws

30 april 2024 · I-MAB Filed 2023 Annual Report on Form 20-F · Persbericht

5 april 2024 · I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

2 april 2024 · I-Mab Announces Closing of the Divestiture of Business Operations in China · Persbericht

14 maart 2024 · I-Mab Reports Full Year 2023 Financial Results and Business Update · Persbericht

7 februari 2024 · I-Mab Signs Agreement to Divest its Assets and Business Operations in China · Persbericht

6 november 2023 · I-Mab Announces Participation at Jefferies and Piper Conferences in November · Persbericht

2 november 2023 · Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) · Persbericht

1 november 2023 · I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 · Persbericht

16 oktober 2023 · I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 · Persbericht

10 oktober 2023 · I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 · Persbericht

Profiel I-Mab

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Werknemers: 141

Aandelen I-Mab

Beurswaarde: 145,26 miljoen USD

Effecten: 80,70 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe